{"title":"研究重点","authors":"Hajrah Khawaja","doi":"10.1111/febs.17315","DOIUrl":null,"url":null,"abstract":"<p>In this issue of <i>The FEBS Journal</i>, we highlight a study by Madine <i>et al.</i> that explores a potential treatment strategy for light-chain amyloidosis, and a report by Shortt and colleagues investigating how immunomodulatory imide drugs can impact the cereblon interactome. We also feature work by Polikarpov and co-authors exploring how the enzyme <i>Bl</i>Est2 could be the founding member of a previously unrecognised subgroup of carboxylesterases. Image created using Wordclouds.com.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":94226,"journal":{"name":"The FEBS journal","volume":"291 22","pages":"4890-4891"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/febs.17315","citationCount":"0","resultStr":"{\"title\":\"Research highlights\",\"authors\":\"Hajrah Khawaja\",\"doi\":\"10.1111/febs.17315\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In this issue of <i>The FEBS Journal</i>, we highlight a study by Madine <i>et al.</i> that explores a potential treatment strategy for light-chain amyloidosis, and a report by Shortt and colleagues investigating how immunomodulatory imide drugs can impact the cereblon interactome. We also feature work by Polikarpov and co-authors exploring how the enzyme <i>Bl</i>Est2 could be the founding member of a previously unrecognised subgroup of carboxylesterases. Image created using Wordclouds.com.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":94226,\"journal\":{\"name\":\"The FEBS journal\",\"volume\":\"291 22\",\"pages\":\"4890-4891\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/febs.17315\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The FEBS journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/febs.17315\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The FEBS journal","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/febs.17315","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
In this issue of The FEBS Journal, we highlight a study by Madine et al. that explores a potential treatment strategy for light-chain amyloidosis, and a report by Shortt and colleagues investigating how immunomodulatory imide drugs can impact the cereblon interactome. We also feature work by Polikarpov and co-authors exploring how the enzyme BlEst2 could be the founding member of a previously unrecognised subgroup of carboxylesterases. Image created using Wordclouds.com.